



Fig. S2. Serum interleukin (IL)-17A, IL-17F, IL-12p70, and IL-23 levels before and during ustekinumab therapy as measured by digital enzyme-linked immunoassay (ELISA). Ustekinumab was injected subcutaneously after sampling on days 0, 28 and 111, indicated with orange arrows.